Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus
CEO Martin Vidaeus of Redwood Pharma updates industry and shareholders of the status of the RP101 Phase II trial at the Bio-Stock forum on December 3, 2019 in Stockholm, Sweden. About RP101RP101 is a novel, topical treatment for post-menopausal women suffering from chronic, moderate-to-severe dry eye disease (DED), and consists of a low-dose estrogen analog formulated in a proprietary controlled-release drug delivery platform, IntelliGel. The active substance has already been proven safe and efficacious in two Phase II clinical trials conducted in the US. Redwood Pharma is currently